It is becoming more apparent each day that despite a strong national commitment to excellence in health care, the resources and personnel are finite. It is, therefore, appropriate that the medical profession examine the impact of developing technology on the practice and cost of medical care. Such analysis, carefully conducted, could potentially have an impact on the cost of medical care without diminishing the effectiveness of that care.
Preamble
It is becoming more apparent each day that despite a strong national commitment to excellence in health care, the resources and personnel are finite. It is, therefore, appropriate that the medical profession examine the impact of developing technology on the practice and cost of medical care. Such analysis, carefully conducted, could potentially have an impact on the cost of medical care without diminishing the effectiveness of that care.
To this end, the American College of Cardiology and the American Heart Association in 1980 established a Task Force on Assessment of Diagnostic and Introduction to Acute Myocardial Infarction Coronary artery disease is the leading cause of death in the United States. Despite an encouraging 47% reduction in age-adjusted coronary mortality rates over the past 25 years, coronary disease caused 514,000 deaths in 1987.1 There were approximately 750,000 patients admitted to hospitals with acute myocardial infarction during 1987 in the United States.2 There are roughly 7 million patients with diagnosed coronary disease in this country and many more with clinically silent coronary atherosclerosis. Morbidity and mortality in patients with coronary artery disease in general, and in heart attack victims in particular, are in large part determined by the extent of heart muscle damage as well as the number and severity of coronary atherosclerotic lesions.
Developments in Treatment of Myocardial Infarction
From the time the myocardial infarction syndrome was first related to coronary thrombosis in 1912 through the 1940s, treatment progressed slowly, with no landmark changes except, perhaps, the introduction of oral anticoagulant therapy. There were interminable debates about digitalis usage and the length of absolute bed rest needed in the treatment of such patients. In the late 1950s, coronary care units were developed. With development of direct current defibrillators and closed chest cardiopulmonary resuscitation in the 1960s, a significant impact was made on the early mortality rate of myocardial infarction. The 1960s also saw the development of hemodynamic monitoring of patients with myocardial infarction and recognition of hypovolemia as a correctable cause of shock in a percentage of such patients. Finally, the development of counterpulsation improved survival in the patients with pump failure, but only to a minimal extent. The 1970s witnessed more universal training of medical and nonmedical personnel in cardiopulmonary resuscitation and deployment of mobile coronary care units (first developed by Pan- tridge and Geddes in 19673). The 1970s saw use of pharmacologic methods for myocardial preservation by improvement of nutrient supply to the myocardium through interstitial diffusion using hyaluronidase or glucose-insulin-potassium solution and decrease in myocardial oxygen requirements with use of ,3-adrenergic blockers and unloading agents.
Physicians in Spokane, Washington, made the next major leap forward by providing reperfusion through early coronary artery bypass surgery. 4 DeWood et a15 presented convincing evidence that there was thrombosis of the coronary artery early in myocardial infarction and this thrombus likely had spontaneous lysis over the ensuing hours in some patients. The surgical experiences in Spokane and later in Iowa6 were outstanding tours de force in reperfusion by surgical thrombectomy and coronary bypass, but did not lead to universal application because of logistic impracticality.
In 1976, Chazov et a17 reported on intracoronary fibrinolysis in acute myocardial infarction. Rentrop et a18 used catheter-directed reperfusion by mechanically opening the artery and then using intracoronary thrombolytic agents. As time went on, it became clear that the delay while waiting for intracoronary thrombolytic agents was using up the time window for best myocardial salvage by reperfusion. Thus, the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) trial,9 the first large scale study of early intravenous thrombolysis, is the milestone that marks the beginning of the era of routine thrombolysis in patients with early acute myocardial infarction. The development of the second generation thrombolytic agents that are more clot-specific may well improve the safety and efficacy of thrombolysis. The third generation, which may be represented by single chain pro-urokinase, could further improve safety and efficacy; however, despite hope for further improvements, there is little doubt that patients who receive thrombolytic reperfusion early in acute myocardial infarction and are not excluded from thrombolytic therapy by specific contraindicators show significantly improved survival9-12 and ventricular function. 13 Current Guidelines for Treatment In this review, it is incumbent to establish as best we can current guidelines for treatment of acute myocardial infarction, including the current use of thrombolytic agents. We recognize that we are shooting at a moving target, but enough has been established that we think guidelines can be developed appropriately and must be developed at this time. These guidelines should not be considered rigid; rather they are guides to be modified by clinical judgment and individualpatient needs. The next major step may well be newer methods of preserving or preventing further destruction of the myocardium after temporary occlusion using such agents as oxygen-free radical scavengers. However, these interventions are still in the discovery phase and are not appropriate for our guidelines at this time.
Throughout this report, we have used the following classification of indications for diagnostic procedures and therapeutic interventions:
Class I: Usually indicated, always acceptable, and considered useful/effective
Class II: Acceptable, of uncertain efficacy, and may be controversial a: Weight of evidence in favor of usefulness/efficacy b: Not well established by evidence, can be helpful, and probably not harmful Class III: Not indicated, may be harmful
Role of Patient Education in Early Treatment
Patients with acute myocardial infarction can receive optimal medical management only when they seek medical care early in the course of the illness. Many current strategies for care, including thrombolytic therapy, are most effective when started early in the course of infarction. Treatment for lifethreatening complications of infarction, including ventricular fibrillation and cardiogenic shock, is, of course, available only to patients who are under medical observation when these events occur. Because of the extreme importance of early medical care in the treatment of acute myocardial infarction, the portion of the adult population at risk of having an acute infarction must be educated about the symptoms of infarction and how to seek emergency cardiac care in their community. It is the obligation of physicians who care for patients with known coronary artery disease as well as those receiving medical care for illnesses that increase the risk of myocardial infarction (for example, diabetes, hypertension, and peripheral vascular disease) to educate their patients about the recognition of and response to symptoms of infarction. Emergency Care Systems Each community must take the responsibility of developing a plan for the early management and triage of patients with suspected acute myocardial infarction. When possible, the emergency care system should have a group of well trained emergency medical technicians who have a physician-directed plan for the care of these patients.
Evaluation of patients in the field should be carried out with a specific protocol. Patients should be evaluated rapidly and transferred to a nearby hospital equipped to manage patients with acute myocardial infarction. Patients who are critically ill, such as those who have had a cardiac arrest, have repetitive episodes of ventricular tachyarrhythmias, or severe bradycardia or are in shock, should be taken to a hospital with cardiac catheterization and cardiac surgery facilities instead of to a smaller community hospital without such facilities if this will not require excessive transport time. Plans for the triage of critically ill patients to a tertiary hospital should be part of every community plan.
Emergency departments must be able to rapidly assess patients with suspected myocardial infarction. The emergency department must make every effort to identify patients with suspected acute myocardial infarction when they enter the department. Patients with chest pain, chest tightness, acute epigastric distress, and other symptoms suggestive of acute myocardial infarction must be evaluated quickly and, when appropriate, placed on a protocol. These patients should have electrocardiographic (ECG) monitoring from the time of entry, an immediate full ECG, frequent vital signs, and be seen by a physician within the first few minutes of arrival in the emergency department. Delays in evaluation and treatment related to hospital administrative procedures, such as establishing insurance coverage, must not be allowed to occur.
In patients in whom the clinical presentation and ECG are characteristic (classic) of acute myocardial infarction, the initial therapy, including appropriate use of thrombolytic therapy, should be begun by the appropriately trained emergency department physician and staff. When the diagnosis of acute myocardial infarction is less certain, consultation with an immediately available cardiologist or internist should be obtained. Prolonged efforts to consult with the patient's private physician are inappropriate if this is likely to result in a significant delay in initiating specific therapy.
In rural communities, patients with acute myocardial infarction will often receive their initial care in hospitals with limited special facilities and without physicians with special training in acute cardiac care. In this situation, plans should be developed with nearby medical centers for rapid telephone consultation and appropriate patient transfer to a tertiary medical center. In many circumstances, protocols for the initiation of thrombolytic therapy in the rural hospital before transfer are appropriate and have been shown to be safe and effective.
Other Considerations
In this document we only touch on treatment of arrhythmias and do not discuss modification of risk factors. This should not reflect their lack of importance, but rather a decision that they have been treated well elsewhere and are outside the scope of this document.
Oxygen
Even with uncomplicated myocardial infarction, some patients are modestly hypoxemic initially. Although the exact mechanism for this hypoxemia is uncertain and may be complex, it is likely that ventilation-perfusion mismatch plays a prominent role.14 Patients with associated congestive heart failure have more severe hypoxemia.
Supplemental oxygen should be provided at least in the initial hours for all patients suspected of having acute ischemic pain. Oxygen should not be withheld during transportation to the hospital, even if there is evidence of chronic pulmonary disease; however, lower flow rates may be prudent in these patients.
Patients with severe congestive heart failure, pulmonary edema, or a mechanical complication of acute myocardial infarction may fail to correct significant hypoxemia with supplemental oxygen alone.
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Endotracheal intubation and mechanical ventilation are often required in such cases and should not be unnecessarily delayed.15 Nitroglycerin For more than 100 years nitroglycerin has relieved the pain of myocardial ischemia for patients suffering from coronary artery disease. This benefit is achieved by the actions of nitroglycerin to dilate epicardial conductance arteries, increase collateral blood flow to ischemic myocardium, and decrease left ventricular preload.
Initial Use of Nitroglycerin
Patients presenting with ischemic pain should receive sublingual nitroglycerin unless the initial systolic blood pressure is <90 mm Hg. Even if the systolic blood pressure is <90 mm Hg, a single sublingual nitroglycerin tablet may be tried in the hospital, provided there is evidence of ongoing ischemic pain and an intravenous line has been inserted. Nitroglycerin should be avoided in the presence of marked bradycardia or tachycardia, especially if relative hypotension is present. 16 Careful and frequent observation of vital signs is necessary for several minutes after the initial dose.
Long-acting oral nitrate preparations should be avoided in the management of early acute myocardial infarction. Sublingual or transdermal nitroglycerin can be used, but intravenous infusion of nitroglycerin allows for more precise minute to minute control of this agent. Intravenous nitroglycerin can be successfully titrated by frequent measurement of cuff blood pressure and heart rate. Although invasive hemodynamic monitoring is not 
Effect of Intravenous Nitroglycerin on Infarct Size and Mortality
There is experimental and clinical evidence18-20 that intravenous nitroglycerin may reduce infarct size in some patients. As with all interventions designed to salvage myocardium, the best results occur when treatment begins early. Nitroglycerin may decrease susceptibility to ventricular fibrillation during both acute myocardial ischemia and reperfusion. 21 Metaanalysis of the pooled results of 10 studies seemed to demonstrate that intravenous nitrates also reduce mortality by 10% to 30%. 22 One recent randomized trial20 on intravenous nitroglycerin in 310 patients demonstrated improved hospital survival (mortality rate 14% versus 26%, p<0.01) that was limited to patients with anterior infarction. This benefit was sustained for 1 year.20 Despite these considerations, however, there are inadequate data at present to recommend infusion of intravenous nitroglycerin in all patients with uncomplicated acute myocardial infarction.
Whatever its theoretic value in reducing infarct size and mortality, however, intravenous nitroglycerin is of uncontested value in suppressing ongoing myocardial ischemic pain. Its benefit is also well established when acute myocardial infarction is complicated by congestive heart failure or pulmonary edema. ' Atropine is the drug of choice for the occasional treatment of type I second-degree AV block, especially when complicating inferior myocardial infarction. It is rarely useful in third-degree AV block. When AV block or sinus bradycardia is associated with congestive heart failure, hypotension, or frequent and complex ventricular arrhythmias, atropine may improve AV conduction and increase the sinus rate and may avert the need for immediate insertion of a transvenous pacemaker.31 As a rule, however, in the absence of hemodynamic compromise, treatment of sinus bradycardia and AV block is not indicated. Similarly, atropine is rarely, if ever, the drug of choice for management of type II second-degree AV block. On occasion, while failing to improve AV block, atropine may increase the sinus rate and, in fact, enhance the block.
The recommended dosage of atropine for bradycardia is 0.5 mg intravenously, repeated if needed every 5 minutes to a total dose of no more than 2 mg, the amount that produces complete vagal blockade. Atropine may also be therapeutic in ventricular asystole, for which the recommended dose is 1 mg intravenously, to be repeated in 5 minutes (while cardiopulmonary resuscitation continues) if asystole persists. The total cumulative dose should not exceed 2.5 mg over 2.5 hours. The peak action of atropine given intravenously is observed within 3 minutes.
Side Effects
Atropine in doses of <0.5 mg or when administered other than intravenously may result in a paradoxic effect (namely, bradycardia and depression of AV conduction).32 The effects are due either to central reflex stimulation of the vagus or to peripheral parasympathomimetic effect on the heart. Repeated administration of atropine may produce adverse central nervous system effects, including hallucinations and fever. Careful observation is necessary after the administration of atropine because the sinus tachycardia that follows may increase ischemia. Rarely, ventricular tachycardia and fibrillation occur after the intravenous administration of atropine. 33 Pacemaker insertion is the treatment of choice for symptomatic bradycardia not responding promptly to atropine administration (see elsewhere). Recommendations 
Lidocaine
In the presence of acute myocardial infarction, lidocaine is the drug of choice for the management of ventricular ectopic beats and arrhythmia, including ventricular tachycardia and ventricular fibrillation. 35 Suppression of premature ventricular contractions applies the concept that with myocardial ischemia, the threshold for ventricular fibrillation is reduced and premature ventricular contractions may trigger ventricular fibrillation. Even though premature ventricular contractions in the presence of myocardial ischemia may be successfully suppressed, ventricular fibrillation may still occur. Moreover, although lidocaine reduces the incidence ofventricular arrhythmia, including ventricular fibrillation, trials36,37 have failed to demonstrate that suppression of premature ventricular contractions significantly reduces overall mortality in acute myocardial infarction. There appears to be an increased incidence of asystole with lidocaine and this may obscure the favorable influence of suppression of premature ventricular beats. 38 Generally accepted indications for the use of lidocaine in acute myocardial infarction include ventricular premature beats that are 1) frequent (> 6/min), 2) closely coupled (R on T phenomenon), 3 ) multiform in configuration, or 4) occur in short bursts of three or more in succession. Lidocaine should also be used for the treatment of ventricular tachycardia and ventricular fibrillation that is resistant to defibrillation. Dosage A loading dose or multiple bolus injections are necessary to initiate lidocaine therapy and to achieve therapeutic blood levels rapidly.39 An initial intravenous bolus injection of 1 mg/kg, not to exceed 100 mg, is recommended. Additional bolus injections of 0.5 mg/kg can be given every 8 to 10 minutes if necessary, to a total of 4 mg/kg. Maintenance of blood levels is accomplished by the administration of 20 to 50 gg/kg/min (1.4 to 3.5 mg/min in a 7 kg patient). This produces blood levels of 2 to 5 ,ug/ml of blood. 40 Patients who require more than one bolus dose of lidocaine to effect suppression of extrasystoles may require higher maintenance doses of lidocaine as well (up to 40 to 50 gg/kg/min). 41 The elimination is almost exclusively by the liver. Its half-life averages 1 to 2 hours in normal subjects, >4 hours in patients with relatively uncomplicated myocardial infarction, >20 hours in patients with myocardial infarction complicated by cardiac failure, and even longer in the presence of cardiogenic shock and therefore there will be a need to reduce the infusion rate of lidocaine appropriately in these patients. 41 Patients treated with an initial bolus injection followed by a maintenance infusion may experience transient subtherapeutic plasma concentration at 30 to 120 minutes after initiation of therapy. A second bolus injection of 0.5 mg/kg without increasing the maintenance infusion rate reestablishes a therapeutic serum concentration. If arrhythmia recurs after 6 to 10 hours (that is, at a steady rate of infusion), a similar bolus injection should be given and the maintenance infusion rate increased. Increasing the maintenance infusion rate without an additional bolus injection results in a very slow increase in plasma lidocaine concentration, taking >6 hours to reach a new plateau. 41 Although the treatment of choice for ventricular arrhythmias during the acute phase of myocardial infarction is lidocaine, an occasional patient may be refractory to lidocaine or the arrhythmia may persist past the acute phase. Discussion of the pharmacotherapy of these arrhythmias is beyond the scope of this report, other than to suggest that procainamide and quinidine are probably the drugs of choice. For discussion of the indications for electrophysiologic study for selection of drugs, the reader is referred to the ACC/AHA Guidelines for Clinical Intracardiac Electrophysiologic Studies. 48 Similarly, for indications for implantable defibrillators, the reader is referred to the ACC/AHA Guidelines for Permanent Cardiac Pacemaker Implantation (in press).
Supraventricular arrhythmias, although relatively frequent, are rarely life-threatening. When complicating acute infarction, their management as a rule does not differ from that for similar arrhythmias complicating other cardiac disorders. The discussion of therapy of these arrhythmias is similarly beyond the scope of this report.
Use of Pacemakers in Acute Myocardial Infarction
Although it is difficult to demonstrate statistically significant improvement in survival with use of temporary pacing in acute myocardial infarction, there are accepted indications and the general impression that some patients are saved. 49 Patients with progressive heart block usually have a large infarct and it is the loss of myocardium that leads to death in many temporarily saved by pacing. There is a small but significant incidence of complications from temporary pacing and this includes induction of arrhythmias, ventricular perforation, pneumothorax, hemothorax, arterial injury, and infection. 50 Transfer should be arranged on a physician to physician basis. The patient must be accompanied by a complete medical record. 54 Emergency transportation must be in a vehicle equipped and staffed for advanced life support. Inordinate delays at the sending facility should be avoided, but stabilization of the patient's condition should be achieved to the extent possible before and during transportation of the patient to the receiving hospital. A physician need not accompany the patient during transportation, but must see to it that the patient is in stable condition before transfer and will be treated quickly by a physician on arrival at the receiving hospital.
Direct voice communication with the receiving hospital is essential during transportation. Radio contact assures rapid access to medical direction. Electrocardiographic monitoring and emergency medications are essential. Equipment for endotracheal intubation and suction, esophageal obturator airway maintenance, direct current defibrillation, and external pacing are necessary. 55 Patients who should be transferred include (but are not limited to) those who have undergone acute thrombolysis and continue to experience angina or other evidence of continuing ischemia of viable myocardium. These patients should be in a facility with the staff and equipment required to perform coronary angioplasty and emergency cardiac surgery.
Air Versus Surface Transportation
During transportation, safety of the patient and personnel are of foremost importance. If the patient's condition has been stabilized and if thrombolytic therapy has been given, haste in the transportation process is secondary to safety. Whether transportation is by surface or by air will depend on the distance and local capabilities. Studies56 of helicopter transfer of patients with acute myocardial infarction who have or have not received intravenous fibrinolytic therapy have indicated that this can be done safely. Arrhythmias, hypotension, and bleeding have been treated during transit without mortality. 56 The advantage of helicopter transport pertains as much if not more to the personnel and equipment for communication as to this specific mode of transportation. Aircraft safety is an important and controversial issue and cost/benefit ratio is still being determined. Crashes, deaths, and injuries have occurred during aeromedical transport of critically ill patients.
If surface transportation to the receiving hospital required >90 to 120 minutes, air transportation should be considered. Transportation has been performed safely by ambulance for approximately 60 miles with a paramedic but no physician in attendance. 57 In one series,57,58 33% of patients developed complications including ventricular arrhythmias requiring cardioversion, myocardial infarction, or hypotension requiring treatment during transport; only 1 of 50 patients died.
It is important to utilize the following pretransfer checklist to avoid mishap and anticipate problems59:
* Detection and Quantification of Acute Myocardial Infarction A strong history of the typical manifestations of myocardial ischemia and positive risk factors coupled with salient physical findings of acute myocardial infarction are of inestimable value in diagnosis. With a suggestive history, the probability of infarction is enhanced in the presence of detectable ventricular ectopic activity, sinus tachycardia, bradycardia, or accelerated idioventricular rhythm. Findings that more directly reflect myocardial injury are palpable dyskinesia, pulsus alternans, hypotension, a soft S1, paradoxic splitting of S2, an accentuated S4 or an S3, murmur of mitral regurgitation, and signs and symptoms of congestive heart failure. Manifestations of excessive autonomic nervous system activity support the diagnosis. Involvement of the right ventricle in patients with inferior infarction is often recognizable by ST segment changes in ECG leads V3R and V4R, elevated venous pressure, and hypotension disproportionate to left heart failure. The Killip classification has been useful for clinical assessment of the severity of infarction. However, more objective and definitive information can be acquired with noninvasive techniques (for example, two-dimensional echocardiography or radionuclide ventriculography) that permit serial assessment, quantification and localization of regional wall motion abnormalities, and delineation of global left and right ventricular function. 60 Definitive diagnosis is based on objective criteria; despite the occasional occurrence of electrocardiographically silent infarction, there are frequently nondiagnostic ECG changes and, therefore, sequential ECG changes remain a mainstay of early diagnosis. Infarction cannot be established with certainty in the absence of alterations of the QRS complex, but ST segment deviation, T wave abnormalities, intraventricular conduction delays, changes indicative of right ventricular infarction in right-sided precordial leads, and nonspecific changes in rate and rhythm are suggestive of infarction.
Laboratory Criteria
Detection of the release of macromolecules from irreversibly injured myocardium. This has evolved as the definitive diagnostic criterion of infarction. Enzymes that egress from ischemic myocardium within several hours after the onset of irreversible injury include aspartate aminotransferase, lactate dehydrogenase, and creatine kinase (CK). Elevated activity in plasma is a sensitive diagnostic criterion, although its specificity is somewhat limited because of potential liberation of enzyme from skeletal muscle or other tissues. The MB isoenzyme of creatine kinase has become a cornerstone of diagnosis because it is much more abundant in myocardium ACCIAJIA Task Force Management of Acute Myocardial Infarction 675 than in most other human tissues.61 Necrosis of <0.1 g of myocardium can be recognized. Assessment of posttranslational conversion of individual isoenzymes of creatine kinase to subforms (isoforms) provides criteria for even earlier detection of infarction and permits recognition of recanalization by increased washout of the tissue subform into plasma.62-65 Analysis of isoenzymes of other enzymes such as lactate dehydrogenase provides less specific information. These macromolecules are elaborated from components of the inflammatory response accompanying infarction and hemorrhage within the heart as well as from the myocytes themselves.
Assays of macromolecules such as myosin light chains65 and myoglobin.66 Such assays may be valuable in clarifying elusive diagnoses because of their characteristic rates of appearance and disappearance. Interpretation of changes in plasma concentrations of macromolecular markers of infarction may be obscured when rates of release are altered by recanalization or profound ischemia. When appearance rates are very slow compared with disappearance rates, dilution of the marker in plasma may mask elevations that otherwise would be apparent. 61 Sequential changes in plasma concentrations of macromolecular markers such as creatine kinase are useful in estimating the extent of infarction. 61 In view of the specificity and sensitivity of the MB isoenzyme of creatine kinase in plasma as a marker of myocardial injury, assay of other plasma enzymes is generally not necessary. These assays may be useful when a patient with suspected infarction is admitted several days or more after the onset of symptoms, by which time MB CK elevations may no longer persist, or if the time of onset of infarction is uncertain. 61 Isoform analyses. Recent recognition62-64 of isoforms and characterization of the kinetics of their formulation in plasma by proteolysis of isoforms released from the myocardium underlie an approach for very early detection of infarction and noninvasive detection of reperfusion. Although creatine kinase isoform and myoglobin analyses are still investigational, likely uses are monitoring the efficacy of pharmacologic thrombolysis, defining the need for invasive studies or interventions, and facilitating interpretation of episodes of chest pain. Elevations Two-dimensional echocardiography consistently localizes impaired wall motion associated with anterior infarcts and that associated with inferior infarcts in >90% of patients.67 Contrast echocardiography may permit estimation of the extent of infarction by delineating hypoperfusion in the region at risk, although its use for this purpose is primarily in research and its implementation requires a practiced technique and dedicated instrumentation.68 Wall thinning or the lack of wall thickening is an important ancillary finding. Global measures of left ventricular performance are less sensitive and specific than assessments of regional wall motion in detecting, localizing, and qualifying the extent of ischemic insults.
Assessment of global and regional ventricular performance by radionuclide ventriculography has a sensitivity and specificity comparable with those of echocardiography and provides estimates even in patients with anatomic features precluding adequate echocardiographic examination. Cost and radiation exposure are considerations.69
Sensitivity, specificity, spatial resolution, and quantitative power of contrast ventriculography are superior to those with any conventional noninvasive method. Expense, radiation exposure and risk 'associated with left heart catheterization and administration of radiographic contrast agents are disadvantages.
Assessment by cine computed tomography and nuclear magnetic resonance imaging. Several novel techniques have been developed for delineating abnormal ventricular function indicative of acute myocardial infarction, including ultrafast (cine) computed tomography.70 Instrumentation is expensive, radiation burdens are significant, and applicability is limited. Gated nuclear magnetic resonance (NMR) imaging with or without paramagnetic contrast agents such as gadolinium-DTPA detects reversible and irreversible myocardial injury induced by ischemia in experimental animals and patients.71 Spin-echo images show increased signal intensity corresponding with dyskinetic segments, reflecting acute myocardial infarction72 or zones with diminished perfusion evident in contrast studies. 71 predisposing to left ventricular mural thrombi, detecting thrombi already present and facilitating assessment of the predisposition of thrombi for embolization. In patients in whom left bundle branch block, a paced rhythm, posterior infarction, or non-Q wave infarction is present, the diagnostic power of the ECG for infarction may be somewhat limited. Under these circumstances, detection of infarction and delineation of its locus and extent can be facilitated greatly by echocardiography.
Diagnosis ofAcute Myocardial Infarction
In addition to history and physical examination, patients with suspected acute myocardial infarction should be evaluated with a chest X-ray study, serial ECGs, possibly several within a few hours, and MB CK determinations.75 Subsequent ECGs are needed daily until the nature of evolution of infarction is defined and more frequently if complications occur. Plasma MB CK (or total CK if MB assays are not available) should be measured at 6 hour intervals for the first 24 hours and then daily until the diagnosis is established or, in the absence of complications, until values have returned to baseline. Determination of levels of other plasma enzymes, such as aspartate aminotransferase and lactate dehydrogenase, are not necessary except in unusual circumstances such as when admission is days after suspected infarction at a time lactate dehydrogenase may still be elevated but MB CK has returned to normal.
Indications for Assessment of Left Ventricular Function in the Early Phase ofAcute Myocardial Infarction
Assessments of left ventricular function can be made expeditiously by echocardiography, radionuclide ventriculography, and other imaging techniques. The selection of the particular modality used in a given institution should depend in part on the familiarity and expertise of the institution with each specific method. It is inappropriate to acquire duplicate information with different methods unless specifically indicated. hours of the onset of symptoms, the 7-day mortality rate was reduced from 4.3% to 3.7% (p<0.02). Favorable trends of similar magnitude were also apparent for reinfarction and cardiac arrest (or ventricular fibrillation). The 14% mortality difference between the treated and nontreated groups was apparent by the end of day 1 and remained essentially constant thereafter. p-Blockade was initiated in this study as 5 to 10 mg of atenolol (intravenously) and continued at a level of 100 mg orally/day for 1 week. In the second largest study,78 the 15-day mortality rate in >5,700 patients was reduced from 4.9% to 4.3%, with the difference in mortality between treated and placebo groups again evident at day 1. It was suggested that the beneficial effect of pl-blockade was largest in "high-risk" subgroups, as defined by either prestudy risk predictors or a multivariate risk model. The p-blocker employed was metoprolol in a dose of up to 15 mg intravenously in three divided doses (with 2-minute intervals between) and, starting 15 minutes after completion of the intravenous dosage, 50 mg orally every 6 hours for 48 hours then 100 mg twice daily thereafter.
Recommendations for Echocardiography in the Early
Assessment of effects of acute P-blockade on indexes of infarct size are complicated by differences in study design (for example, frequency of enzyme sampling, time of initiation of P-blockade in relation to onset of symptoms, approaches to ECG evaluation) and study size. Review of available studies76 is consistent with the view that modest favorable effects occur. Thrombolytic agents were not administered in these studies.
A recent trial79 of early P-blockade in conjunction with thrombolytic therapy showed no adverse effect of the combined therapy and a suggested reduction in frequency of reinfarction compatible with findings in the larger studies. [76] [77] [78] Because several p8-blocking agents (both cardioselective and nonselective) have been employed in the studies cited, beneficial effects of ,B-blocking agents do not seem limited to any particular member of the drug group. Agents having intrinsic sympathomimetic activity as well as ,-blocking activity may be less desirable and should be avoided. Intravenous 13-blocking agents with extremely short durations of activity may prove advantageous in selected patients. The Diltiazem Reinfarction Study Group88 reported that in the dose of 90 mg every 6 hours, initiated within 24 to 72 hours after onset of infarction, diltiazem was effective in preventing early reinfarction and recurrent angina in patients with non-Q wave infarction (formerly designated nontransmural or subendocardial infarction). The study of long-term diltiazem therapy in patients with both Q wave and non-Q wave myocardial infarction failed to demonstrate a beneficial effect of diltiazem. Although there were slightly fewer recurrent cardiac events overall in the diltiazem group as opposed to the placebo group, this did not reach statistical significance. In patients receiving diltiazem, there appeared to be an adverse effect in the small group of patients with left ventricular dysfunction and this may have obscured the favorable effects in patients with normal ventricular function, but this was not tested prospectively. Thus 10 have reported baseline and outcome data in 17,187 patients with suspected myocardial infarction who were recruited within 24 hours of the onset of chest pain. These patients were randomized to intravenous streptokinase (1.5 mU over 60 minutes), oral aspirin (160 mg/day for 1 month), to both or to neither in a double-blind fashion by means of matching placebos. Patients were excluded from the trial if >24 hours had elapsed from the onset of symptoms, whereas most other trials used either a 6-hour or 12-hour exclusion, and there was no age limit, which ranged from 70 to 75 years in other trials. The issues to be tested were the effect of streptokinase on the vascular mortality rate at 5 weeks and later and the effect of aspirin on the 5-week vascular mortality rate. In addition, a subsidiary analysis was planned of the effect of streptokinase on the vascular mortality rate in those treated <4 hours after the onset of pain, 4 to 12 hours after pain, and at 12 to 24 hours.
When the data were analyzed for mortality at 5 weeks after trial entry, the ISIS-2 investigators10 observed that the 8,592 patients assigned to streptokinase treatment experienced 786 (9.1%) vascular deaths compared with 1,016 such deaths (11.8%) in the 8,595 patients assigned to receive placebo, a 23% reduction (p<0.00001). This difference is similar to the overall 18% reduction noted in the GISSI trial.8,9' In the interval between 5 weeks and 1 year, the estimated vascular mortality rate in the streptokinase and placebo groups was 5.7% and 6.2%, respectively, also similar to that in the GISSI trial (7% mortality in both groups in the interval from 3 weeks to 1 year). The observed 5-week vascular mortality rate in the streptokinase and placebo groups was, respectively, 8.2% and 12.1% (32% reduction) in those treated within 4 hours, 10.3% and 11.8% (13% reduction) in those treated between 4 and 12 hours, and 8.7% and 10.8% (19% reduction) in those treated between 12 and 24 hours. In patients treated within 1 hour, the 5 week vascular mortality rate was reduced by 42% in the streptokinase group (similar to the 3-week reduction of 47% in the GISSI trial). Thus, the overall ISIS-2 findings confirm the GISSI results. Earlier treatment appears more effective than late treatment, with substantial benefit to at least 6 hours.
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The ISIS-2 entry criteria did not require ST segment elevation. Review of ISIS-2 entry ECGs revealed that only 56% of the 17,187 patients had ST segment elevation. The remainder had ST depression (8%), bundle branch block (6%), Q waves or T wave inversions (27%), or both, or had a normal study (2%).
ISIS-210 tested 160 mg of aspirin daily for 35 days as an adjunct to thrombolytic therapy. The first dose was given immediately after trial entry. In the 8,587 patients assigned to receive aspirin, there were 800 (9.3%) vascular deaths by 5 weeks compared with 1,002 such deaths (11.7%) in the 8,600 given placebo; this 21% reduction (p<0.00001) is similar in magnitude to the result with streptokinase. The vascular mortality rate between 5 weeks and 1 year was similar (6.0% and 5.8% in the aspirin and the placebo group, respectively). Finally, a comparison of the group assigned to receive both streptokinase and aspirin with the group assigned to neither revealed a 5-week vascular mortality rate of 7.9% (341 of 4,292 patients) and 13.0% (557 of 4,300 patients), a 39% reduction (p<0.00001). In addition to confirmation of the GISSI findings with respect to streptokinase, ISIS-2 provides very strong evidence for a similar and additive effect of aspirin on subsequent mortality in patients with infarction.
Short-term mortality. Mortality data from the GISSI and ISIS-2 studies, with similar smaller supporting trials carried out in The Netherlands, Federal Republic of Germany, New Zealand, and Washington (state) and the ISIS-2 pilot study92-97 provide conclusive evidence that intravenous streptokinase given early in the course of myocardial infarction to patients without contraindications reduces the shortterm mortality rate by 20% to 30%. The In two independent randomized trials, the patency or reperfusion rate, or both, after intravenous rt-PA were compared with those with intravenous streptokinase. In the European cooperative Study,99 129 patients were given either rt-PA or streptokinase intravenously an average of 3 hours after the onset of myocardial infarction. Patency of the infarct-related artery observed approximately 90 minutes after initiation of infusion was 70% and 55% for the rt-PA and the streptokinase groups, respectively (p=0.058). The investigators in the National Heart, Lung, and Blood Institute Thrombolysis in Myocardial Infarction (TIMI) study used a slightly higher dose of rt-PA and encountered a longer delay in starting thrombolytic infusion because of required pretreatment arteriography. They noted a patency rate of 70% and 43%, respectively, 90 minutes after onset of rt-PA and streptokinase infusion in 290 patients treated an average of 4.75 hours after pain onset.100 Thus, the patency rates noted by the two groups of investigators were identical for rt-PA (70%) and varied minimally (55% in the European Cooperative Study and 43% in the TIMI trial) in the streptokinase groups.
The declared TIMI study end point was, however, the proportion of patients entering with closed coronary arteries who experienced reperfusion 90 minutes after initiation of thrombolytic infusion. In 232 TIMI patients with a closed infarct-related artery, the 90-minute reperfusion rate was 62% and 31% for rt-PA and streptokinase, respectively. In addition, as noted in both the European and TIMI studies, perturbation of elements of the clotting system was less marked with rt-PA, although hemorrhagic complications were similar in the streptokinase and rt-PA groups and largely due to hematoma formation at the arterial catheterization site.
Studies after changed formulation of rt-PA. Shortly after completion of the European and TIMI comparisons of rt-PA and streptokinase, the rt-PA production process was changed. The new product, predominantly single-chained, had pharmacokinetic properties that made 100 mg of the new product roughly equivalent to 80 mg of the product used in the TIMI study.101 The rt-PA studies discussed next used the more recent formulation, which is the rt-PA preparation approved for use by the Food and Drug Administration.
Investigators participating in the Anglo-Scandina- Neither of these two trials designed to compare patency or reperfusion of streptokinase and rt-PA was sufficiently large to detect a statistically significant mortality difference. Thus, these trials that have directly compared rt-PA and streptokinase demonstrated that at 90 minutes and with the doses given, rt-PA is a more effective coronary thrombolytic agent with less consumption of clotting factors. The recent comparison of streptokinase and rt-PA reported from New Zealand103 was designed to test the effect of the two agents on ventricular function. The study was a double-blind trial comparing the effect of rt-PA with streptokinase on subsequent (3 week) ventricular function in 270 patients admitted within 3 hours of their first myocardial infarction. A similar ejection fraction was noted (0.58 in both rt-PA-and streptokinase-assigned groups), but mean ejection fraction was not adjusted for patients with an undetermined ejection fraction (such as patients who died before the scheduled ejection fraction determination). The mortality rate at 30 days was 3.7% in the rt-PA group and 7.4% in the streptokinase group (p>0.2). Although there were fewer deaths in the rt-PA group than in the streptokinase group, the trial'03 was too small to draw conclusions about mortality.
The mechanism of mortality reduction with both rt-PA and streptokinase is likely to be thrombolysis with resultant reperfusion, limitation of infarct size, and improved left ventricular remodeling. Accordingly, one might anticipate myocardial salvage and mortality reduction with rt-PA similar to and perhaps larger than that observed with streptokinase, given the observed reperfusion advantage observed with rt-PA. There are currently two large randomized trials involving a direct comparison of streptokinase and rt-PA using death as an end point. GISSI-2 is nearing completion and will probably report data tinal hemorrhage of varying severity can be expected in 5% and genitourinary bleeding in a similar number. However, most hemorrhagic complications in clinical trials have occurred at the site of vascular invasion. Venous and arterial puncture should be kept to an absolute minimum in patients treated with thrombolytic agents and should be cared for meticulously thereafter.
Intracranial hemorrhage after rt-PA may be doserelated. Estimated event rates with 150 mg are on the order of 15-20/1,000 and with a dose of 100 mg, the rate is 5-10/1,000.109 Intracranial hemorrhage after APSAC has not been well defined.
Thrombolytic Therapy in Older Patients
Mortality and case fatality rates with myocardial infarction increase steeply with age. In fact, nearly 50% of all deaths in patients hospitalized for acute infarction occur in those >75 years of age.110 Trials of thrombolytic therapy, with the exception of ISIS-2 and GISSI (which had no age exclusion), have excluded patients >70 years of age (AIMS) or >75 years (ASSET, European Cooperative Study) largely because of a fear of hemorrhagic complications. The ISIS-2 reported a 16% reduction in the 5-week vascular mortality rate (18.2% versus 21.6%) in the streptokinase group >70 years of age at entry, a 26% reduction (10.6% versus 14.4%) in the streptokinase group in those 60 to 69 years and a 28% reduction (4.2% versus 5.8%) in the streptokinase group in <60 years. The GISSI trial noted a 13% reduction in mortality at 3 weeks in those >75 years, an 8% reduction in those 65 to 75 years, and a 26% reduction in those .65 years. The reduction in mortality did not reach statistical significance in the two older categories. Risk of bleeding complications was not tabulated by age in the ISIS-2 or GISSI reports. Given the attenuation of streptokinase effect with increasing age reported in the ISIS-2 and GISSI trials and the paucity of data on use of rt-PA and APSAC in the elderly patient, the administration of thrombolytic therapy to older patients should be judicious with careful screening for potential bleeding risk.
Recommendations for Administration Follow-up Therapy After Thrombolysis Very few data are available regarding management after thrombolytic therapy. Information regarding the effects of various therapeutic agents often used during the acute stage of myocardial infarction (such as /3-blockers, nitroglycerin, and calcium channel blockers) is based on findings from randomized clinical trials that were carried out in patient cohorts that did not receive thrombolytic therapy. The question arises whether one can assume that if an agent was beneficial in clinical trials of myocardial infarction in the absence of reperfusion, it would be similarly beneficial in patients who have received thrombolytic treatment. There are theoretic reasons for believing that this may not be the case. For example, randomized clinical trials of /3-blockers given to patients in the early hours of a myocardial infarction suggest that early mortality rates may be reduced. In contrast, randomized clinical trials comparing calcium channel blockers with placebo in cases with ST segment elevation and transmural infarction have shown no benefit. However, one could postulate that the opposite might be true in the patient who has had successful reperfusion. Recanalization may enhance vasomotor activity in the infarct-related artery consequent to the liberation of vasoactive substances from platelet aggregation. Under these circumstances, a calcium channel blocker such as nifedipine that inhibits coronary vasospasm might be preferable to a ,B-adrenergic receptor blocking drug, which theoretically might result in enhanced coronary vasospasm, reflecting unopposed a-adrenergic activity. This is purely speculative, but serves to emphasize that only a small amount of randomized clinical trial data after reperfusion are currently available.
/3-Blocker Therapy
The TIMI-2 trial79 examined management alternatives in patients after thrombolytic therapy. One arm of that trial dealt with the specific question as to the effect of /3-blockers after thrombolysis. Patients were randomized to receive a /3-blocker immediately or at the end of the first week of hospitalization. Left ventricular ejection fraction was the end point. No statistically significant difference was demonstrated in the group randomized to immediate intervention with a /3-blocker compared with those in whom oral administration was begun at approximately 1 week; however, it was noted that if /3-blockers were given within the first 4 hours after hospitalization, a significant improvement in the rate of nonfatal reinfarction and recurrent ischemia was observed. For patients with infusions started within 2 hours of symptom onset, death or recurrent myocardial infarction occurred significantly less frequently in those treated with intravenous /8-blockade.79 It thus seems reasonable to use /3-blockers as one might in the patient who has not undergone thrombolysis (that is, in patients who demonstrate increased adrenergic activity manifested by tachycardia or hypertension in whom /3-blockers are not otherwise contraindicated). Additionally, patients demonstrating continuing ischemia characterized by recurrent chest pain after thrombolytic therapy presumably will benefit from administration of a /-blocker; however, these patients are also candidates for immediate study in the cardiac catheterization laboratory with a view toward the performance of angioplasty or bypass graft surgery. Finally, if the patient develops atrial fibrillation with a fast ventricular response or develops reflex tachycardia from the use of other agents such as calcium channel blockers or nitrates after thrombolytic therapy, a /8-blocker may prove highly useful in slowing heart rate. Intravenous Nitroglycerin This is a highly effective agent in the patient who has not received thrombolytic therapy, and after thrombolysis it appears to have the same rationale for its use. The coronary vasodilating effects of nitrates and their preload-reducing effects appear to justify their routine use during the first day or two after thrombolytic therapy.
Calcium Channel Blockers
Reocclusion after recanalization is a serious limitation to the benefits of thrombolysis. Spasm has been proposed as playing a role in promoting recurrent occlusion after reperfusion. Hyperreactivity of the coronary vessels exists, as noted earlier, and the particular effectiveness of calcium channel blockers in combating spasm is well documented. A similar experience has been observed in patients after angioplasty. Therefore, although spasm has not been proved as causative in early reocclusion, calcium channel blockade has been suggested. Any of the calcium channel blockers would seem suitable under these circumstances, although the widest experience has been gained with the use of nifedipine, which is the agent that produces the greatest increase in sympathetic tone, and may have to be combined with a 83-blocker to offset the reflex tachycardia. Their use appears reasonable in patients with preserved left ventricular function and coronary artery spasm not responsive to the usual dose of nitrates.
Heparin and Aspirin
One major effort directed to the prevention of rethrombosis is the administration of intravenous heparin. Some physicians begin heparin concomitant with the start of the administration of rt-PA, whereas others give heparin after completion of the rt-PA infusion or after the usual 30-minute to 1-hour infusion of streptokinase. Heparin is normally started in a dose of 600 to 800 IU/hr, often preceded by a bolus injection of 5,000 IU, with the dosage subsequently adjusted to maintain the active partial thromboplastin time between 1.5 and 2 times control values.
It is generally accepted that the usual pathophysiologic basis of acute coronary occlusion leading to acute myocardial infarction is plaque rupture with subsequent thrombus formation. Successful fibrinolysis restores patency of the lumen, but the underlying vascular injury and residual thrombus persist and have active surfaces. For this reason, it is advisable that patients receive both heparin and aspirin. It must be appreciated that the combination of heparin and aspirin may increase the likelihood of a bleeding complication. Low dose aspirin may prove to be effective and the ISIS-2 data10 indicate the daily dose to be 160 mg. Over the next several days if the patient has an uncomplicated course, heparin can be discontinued, although aspirin should be continued indefinitely. An 
Anticoagulants and Platelet Inhibitory Agents
The goals of antithrombotic therapy during and early after acute myocardial infarction include 1) prevention of deep venous thrombosis and pulmonary embolism, 2) prevention of arterial embolization, 3) reduction of early recurrence or extension of myocardial infarction and death, 4) reduction of early reocclusion and death after successful reperfusion with thrombolytic therapy, and 5) secondary prevention of late recurrence of myocardial infarction and death.
Prevention of Deep Venous Thrombosis and Pulmonary Embolism
Introduction. As assessed by indium-125-labeled fibrinogen, the incidence of deep venous thrombosis in the lower limbs of patients with acute myocardial infarction ranges from 17% to 38%, which is similar to the incidence in patients after operation.111 These observations and the increased risk of recurrent myocardial infarction within 3 months of a previous infarction in patients undergoing noncardiac surgery may indicate a hypercoagulable state early after acute myocardial infarction similar to that after major surgery. Deep venous thrombi form early after the myocardial infarction (250% within 3 days), with an incidence that is increased after massive or recurrent infarction with heart failure or cardiogenic shock, prolonged immobilization, and certain characteristics, especially age >70 years."' Low dose heparin started within 12 to 18 hours of the onset of symptoms of acute myocardial infarction and continued for 10 days has successfully reduced the incidence of venous thrombosis in three randomized trials"' from a mean of 23% in 145 control patients to 4% in 138 treated patients. This In patients with chronic left ventricular aneurysm but preserved wall motion outside the zone of infarction, the embolic risk appears considerably lower after 3 months and routine long-term anticoagulation beyond 3 months may not be justified. 17 Recurrence during hospitalization is more common in patients with a smaller infarct (lower plasma enzyme levels). More than half of the early recurrences occur within 10 days and the remainder occur within 14 to 18 days after the initial infarction. In >85% of patients studied, the ECG site of early recurrent infarction has been the same as the initial site. Thus, early recurrence and extension of infarction are nearly synonymous."' There is evidence of frequent spontaneous reperfusion after myocardial infarction and a known incidence of reocclusion after reperfusion, particularly in patients with high-grade residual lesions. The reason for reocclusion may be related to the association of high-grade residual stenosis or residual thrombus providing a very thrombogenic surface, or both.
Anticoagulant and antiplatelet therapy. During and early after hospitalization, can the early recurrence and extension of infarction be prevented by shortterm anticoagulant therapy? In the late 1960s and early 1970s, three randomized, controlled, prospective studies131139120 using heparin followed by low dose anticoagulant therapy (with the equivalent of an INR=2.0 to 3.0), for up to 1 month were significant enough to assess its value. In regard to mortality and reinfarction rates in these three studies, there was only a trend to beneficial results in the patients who had undergone anticoagulant therapy.1"3"19 Chalmers et al"l9 analyzed all of the reported, adequately designed, randomized trials of oral anticoagulants in acute infarction and found, when case fatality ratios were pooled, the small differences in mortality rate in each study became significant by simple chi-square analysis: the overall reduction in mortality rate was 21%; the reduction in the incidence of reinfarction was about 30%.120 It was suggested that all patients without specific contraindications be given anticoagulants during hospitalization for myocardial infarction.' 20 The role of platelet inhibitors in the reduction of the early mortality rate and recurrence (extension) of myocardial infarction was confirmed by the recently reported ISIS-2 study. 10 that are lower than reported in previous years, probably because of more aggressive postlysis antithrombotic approaches.
The TIMI-I investigators'00 observed that after thrombolysis, reocclusion occurred despite continued heparin infusion (activated partial thromboplastin time 1.5 to 2.0 times control value) for 7 to 10 days. Reocclusion was not concentrated within the first few days, but rather occurred throughout the hospitalization. However, in the recent study from Johns Hopkins University,12' no reocclusion during hospitalization occurred when therapy with heparin (activated partial thromboplastin time 2.0 to 3.0 times control value) plus aspirin (325 mg/day) and calcium channel blockade were used. Thus, the role of heparin in adequate dosage plus aspirin appears important for the reduction of reocclusion after thrombolysis.122
Current Recommendations Class I 1. Aspirin (160 mg/day) should be started as soon as the patient is admitted and given daily until discharge from the hospital, at which time it can be continued at a dose of 160 to 325 mg daily. 2. Heparin should be administered together with or immediately after thrombolysis to maintain the activated partial thromboplastin time approximately 1.5 to 2.0 times the control value for 24 to 72 hours.
Secondary Prevention of Late Recurrence of Myocardial Infarction and Death
Introduction. Ten large trials using platelet inhibitor drugs in postmyocardial infarction patients, mostly within the first 2 years, have been conducted. They involved large numbers of patients and were randomized, double blind, and placebo controlled. In eight of these trials, aspirin (at a dose of 300 to 1,500 mg/day) was used alone or combined with dipyridamole. The pooled analysis suggests a significant reduction in the mortality and reinfarction rates (15% and 31%, respectively) in the aspirin group. '23 In patients with unstable angina, the beneficial effect of aspirin in reducing cardiac events continues for the subsequent 2 years, even after the patient becomes stable.'24 Finally, in patients with non-Q wave infarction, long-term treatment with aspirin plus dipyridamole produced a 53% reduction in coronary events. '25 In regard to the use of long-term oral anticoagulants after infarction, 
Summary
Anticoagulation therapy using subcutaneous low dose heparin is recommended for all patients with acute myocardial infarction not receiving thrombolytic therapy. This is begun on admission and discontinued at 48 hours unless the patient is not a candidate for or capable of early ambulation. Those patients with a large anterior infarction, particularly involving the apex of the left ventricle, should be given full dose heparin and switched to an oral anticoagulant (warfarin) when need for invasive evaluation or therapy is no longer contemplated. Oral anticoagulants should be continued for 3 months.
To prevent reocclusion after thrombolysis and for prevention of early and late reinfarction, long-term aspirin therapy should be given as a platelet inhibitor to all patients who can tolerate it. However, in the subgroup of patients with a large anterior myocardial infarction, warfarin may be needed for the prevention of systemic emboli and has benefit for the prevention of early and late reinfarction. Thus, in this subgroup of patients, it may be reasonable to postpone the use of aspirin until anticoagulants are discontinued once the risk of emboli has ceased.
Percutaneous Transluminal Coronary Angioplasty Introduction
The guidelines for the use of percutaneous transluminal coronary angioplasty have been previously published in an ACC/AHA Task Force Report. '29 That report outlines the immediate and long-term effects of elective angioplasty, its risks and contraindications, the selection of patients, and current indications for its use. The present report will elaborate on the indications for angioplasty in patients with acute infarction. The use of angioplasty alone in evolving acute myocardial infarction will be considered separately from the use of angioplasty as an adjunct to thrombolytic therapy.
Primary Coronary Angioplasty
Along with the increasing interest in thrombolysis for the treatment of acute myocardial infarction, there has been interest in mechanical reperfusion by coronary angioplasty. There have been a number of reports130-'35 describing the use of angioplasty alone in the treatment of acute myocardial infarction. These have all been relatively small series and only one134 has been randomized in comparison with an alternative therapy (streptokinase). These studies have generally reported a beneficial effect on left ventricular function, but there has been no good large-scale randomized study comparing this form of treatment with either conventional supportive therapy or the most effective forms of thrombolytic therapy given early during acute infarction.
Percutaneous transluminal coronary angioplasty as the primary treatment strategy suffers from the need to have facilities and personnel for cardiac catheterization and a physician qualified to perform angioplasty available at all times. Because of this, intravenous thrombolysis has become established as the first line of therapy in acute myocardial infarction in suitable patients.
With this background, angioplasty should be considered as primary therapy in acute myocardial infarction only when facilities are available for expeditious transfer to a cardiac catheterization laboratory and where the personnel have the technical expertise and experience in performing angioplasty in this acute situation. Primary coronary angioplasty may appropriately be considered when a hospitalized patient has acute myocardial infarction, a patient presents within 4 hours after onset of symptoms to an institution where adequate facilities and personnel are available, or when thrombolytic therapy is contraindicated. Patients presenting in cardiogenic shock are a special group that may benefit from emergency angioplasty (vide infra).
Although intracoronary thrombolytic therapy is not usually as practical as primary therapy, the use of adjunctive intracoronary thrombolytic therapy during or after an angioplasty procedure may be appropriate when there is evidence of residual thrombus in the artery. In this situation, a smaller dose can be used than that used intravenously (such as 50,000 to 500,000 units of streptokinase or urokinase). Using a smaller dose, particularly <100,000 units, has the advantage of avoiding a systemic lytic effect, therefore minimizing bleeding complications resulting from thrombolytic therapy. Angioplasty After Thrombolytic Therapy Immediate angioplasty. Although intravenous thrombolysis offers the promise of early reperfusion in up to 75% of patients,136 more complete reperfusion may be possible by performing angioplasty in those with a high-grade residual stenosis of the infarctrelated artery and those who failed intravenous thrombolysis. Three well-controlled, relatively large prospective trials79"136"137 have, however, cast doubt on the utility of this strategy when applied early after thrombolysis and in the absence of continued or recurrent ischemia. The TAMI trial,136 European Cooperative Study,137 and TIMI-IIA79 trial of urgent angioplasty failed to demonstrate a significant improvement in global or regional ventricular function in patients undergoing emergency (immediate) angioplasty of infarct-related vessels with a residual stenosis after administration of tissue plasminogen activator compared with patients receiving intravenous tissue plasminogen activator alone and undergoing elective angioplasty (TAMI trial), delayed angioplasty (TIMI-IIA trial), or no angioplasty (European Cooperative Study). The incidence of complications and death associated with emergency angioplasty was significantly greater in those undergoing emergency angioplasty after intravenous rt-PA than in those undergoing intravenous rt-PA administration without emergency angioplasty in the summed results of the three trials. It therefore appears that urgent angioplasty of infarct-related vessels with a residual stenosis after rt-PA therapy has no significant benefit, but does have a significant increase in risk. The failure of angioplasty immediately after thrombolysis may be related to an increased risk of hemorrhagic infarction when angioplasty is performed after administration of tissue plasminogen activator or to an increased risk of rethrombosis. Thrombolytic agents such as streptokinase, urokinase, or tissue plasminogen activator have been shown to cause platelet activation and release of thromboxane A2.138,139 Because thrombolysis is incomplete 1.5 to 3 hours after the administration of an intravenous thrombolytic agent such as tissue plasminogen activator, it is not surprising that angioplasty performed under these circumstances may further predispose to platelet deposition on the residual thrombosis, with subsequent, distal platelet embolization, reocclusion, and death. Whether a similar risk exists with other thrombolytic agents remains to be determined.
Delayed angioplasty. In view of the increased risk of urgent angioplasty after thrombolysis, attention has focused on the role of delayed and elective angioplasty. The need for further revascularization after intravenous thrombolysis relates to the often incomplete thrombolysis and the high incidence of residual stenosis in the infarct-related artery after intravenous thrombolysis. This is in part due to the presence of residual thrombosis and in part to the underlying atherosclerotic lesion. Patients undergoing thrombolysis alone, such as in the GISSI trial9 or the Western Washington trial,96 had a higher incidence of reocclusion and reinfarction than those not given a thrombolytic agent. The significant advantages of early reperfusion in patients with anterior myocardial infarction in the Western Washington trial of intracoronary streptokinase were lost over a year follow-up as a result of reocclusion of the infarct-related artery and reinfarction. In a recent study, Mathey et a1140 reported that patients undergoing coronary artery bypass graft surgery after reperfusion with streptokinase had a better survival rate than patients undergoing thrombolysis alone. The ISIS-2 study, in which aspirin was given in conjunction with intravenous streptokinase, suggested a reduced incidence of reinfarction compared with that from intravenous streptokinase alone. 10 The beneficial result of the use of aspirin in conjunction with intravenous streptokinase in regard to survival, reocclusion, and reinfarction may modify the need for delayed angioplasty. Nevertheless, a high-grade residual stenosis with the potential for recurrent ischemia and infarction persists in many patients after intravenous thrombolysis, suggesting a potential role for delayed or elective angioplasty.
In The Johns Hopkins University trial121 of delayed angioplasty, patients were first randomized to receive tissue plasminogen activator or placebo and then after 48 to 72 hours were rerandomized to undergo or not undergo angioplasty. At follow-up study before hospital discharge, patients undergoing angioplasty had a significant improvement in exercise ejection fraction but not rest left ventricular ejection fraction compared with those not undergoing angioplasty. The risk of angioplasty under these circumstances 48 to 72 hours after infarction does not appear to be appreciably greater than that for elective angioplasty. The advantages of this strategy include avoiding the risk of early angiography, avoiding the risk of emergency angioplasty and achieving a high incidence of final reperfusion, a decrease in the incidence of recurrent ischemic events, and an improvement in exercise-stressed ventricular function. A disadvantage of this strategy is the possible overuse of angioplasty in low risk individuals.
The TIMI-IIB investigators79 examined the strategy of delayed angioplasty in a relatively large number of patients and demonstrated that there was no advantage of this strategy on rest left ventricular ejection fraction or survival compared with a noninvasive strategy in which angioplasty was performed only for postinfarction angina or the development of ischemia on stress testing before hospital discharge. 79 The noninvasive strategy avoids the risk of early angiography and urgent angioplasty. It restricts the use of coronary angioplasty to those at increased risk of ischemic events. The disadvantage of this strategy relates to the failure to identify coronary anatomy and the argument that a submaximal prehospital discharge stress test may not reliably predict recurrent ischemic events, reinfarction, and death.
In view of the failure of available data to demonstrate an advantage of salvage or rescue angioplasty and the failure to show a benefit of routine urgent or delayed angioplasty after successful thrombolysis, it appears that an elective or noninvasive strategy is preferred. Until further data are available from prospective controlled trials, a conservative approach after intravenous thrombolytic therapy seems indicated. This would reserve angiography and angioplasty for patients with postinfarction angina, severe left ventricular dysfunction, or stress-induced myocardial ischemia detected before hospital discharge.
Recommendations for Angioplasty After Intravenous Thrombolysis Class I Dilation of a significant lesion suitable for coronary angioplasty in the infarct-related artery in patients who are in the low risk group for angiographicrelated morbidity and mortality who have a type A lesion (see ACC/AHA Task Force Report on coronary angioplasty129) and: 1. Have recurrent episodes of ischemic chest pain particularly if accompanied by ECG changes (postinfarction angina). 2. Show evidence of myocardial ischemia while on optimal medical therapy during submaximal stress testing performed before hospital discharge or on maximal stress testing in the early posthospital period. 3 The treatment of pump failure should be divided according to hemodynamic subsets and patients may move from one subset to another, requiring change in the therapeutic regimen.'7 Subset 1. Left ventricular filling pressure >15 mm Hg, systolic arterial pressure >100 mm Hg and cardiac index <2.5 1/min/m'. This subset has left ventricular failure; the arterial pressure is sufficiently high to allow for afterload reduction as the first line of therapy.143 It is a subset that, within itself, has a spectrum from hypertension and pulmonary edema to systolic pressures approaching 100 mm Hg, less prominent pulmonary congestion, and more marked evidence of peripheral hypoperfusion. The two vasodilator agents most commonly used are nitroprusside and nitroglycerin. Nitroprusside has the benefit of more active afterload reduction.144 Nitroglycerin has a greater degree of venodilator effect and also relieves ischemia by dilating epicardial coronary arteries. When ischemia is not prominent and the epicardial coronary artery dilator effect of nitroglycerin is not needed, nitroprusside becomes the agent of choice. Conversely, in the early hours of acute infarction when ischemia plays a prominent role in ventricular dysfunction, nitroglycerin may be the more appropriate agent. When using nitroprusside, the patient should be monitored for arterial and left ventricular filling pressures. The initial dose should not exceed 10 ,g/min and increase by 5 gg/min every 10 minutes. If cardiac output increases and the shock syndrome abates, the infusion should be continued. If arterial pressure decreases, tachycardia develops or the cardiac output increase is insufficient, or both, one should add dobutamine beginning at 5 ,ug/kg/min and increase the dose to a maximum of 15 ,ug/ kg/min.'45 Intravenous amrinone with its vasodilating and inotropic effects can also be considered. If arterial pressure decreases more precipitously, dopamine should be substituted for dobutamine. Throughout this period of treatment, use of the intra-aortic balloon pump for counterpulsation should be considered because it is the only treatment that increases coronary blood flow and simultaneously reduces work for the left ventricle. Even in the patient with hypertension who is in pulmonary edema, the balloon pump will tend to lower arterial pressure by its inherent vasodilating effect through double bombardment of the baroreceptors. As one stabilizes the patient with this syndrome, gentle use of diuretic drugs may be indicated if pulmonary congestion continues to be a problem. Pulmonary congestion can often be monitored better by measurement of blood gases combined with changes in wedge pressure than by appearance of rales. ,ug/kg/min is exceeded to maintain arterial pressure, the major effect of the agent is peripheral aadrenergic stimulation and administration of norepinephrine, which has less chronotropic effect, is better. If the patient can be stabilized so that arterial pressure is no longer the problem, the best agent is dobutamine and this can be given simultaneously with the dopamine in the attempt to reduce the dopamine requirement. However, dobutamine is not an agent to be used alone in the severely hypotensive patient.
Subset 3. Right ventricular infarction, elevated right atrial and right ventricular diastolic pressures (>10 mm Hg), <2.5 1/min/m2, systolic pressure <100 mm Hg, and left ventricular filling pressure normal or elevated. These patients are important to recognize because they are very sensitive to volume depletion and frequently respond to volume infusion. They usually, but not always, have inferior wall infarction. There may be varying degrees of left ventricular dysfunction. The principles of therapy differ from those for subset 2 in that right ventricular filling pressure must be increased by rapid administration of fluids until blood pressure is stabilized, left ventricular filling pressure is >20 mm Hg or right atrial pressure is >20 mm Hg. Venodilator agents (such as nitroglycerin) and diuretic drugs (such as furosemide) should be avoided and dobutamine is much preferred to dopamine because the latter tends to increase pulmonary vascular resistance. If volume replacement and mild inotropic support is insufficient, it is useful to know that these patients do respond to intra-aortic balloon counterpulsation and represent a group of patients who, with appropriate therapy (including counterpulsation if necessary), can be discharged in New York Heart Association functional class l. 148 Right ventricular infarction must be differentiated from cardiac tamponade, which is sometimes hemodynamically similar. There are no class I emergency indications for surgery in this subset of patients. Emergency introduction of the intra-aortic balloon pump for cardiac arrhythmias that are incessant or produce hypotension has been helpful in some instances. 151 In patients with aneurysmal expansion of the infarction associated with persistent ventricular tachycardia and failure of medical therapy, surgical resection of the aneurysm and endocardial scar incision along with coronary artery bypass grafting has been successful. 152 In general, intraoperative mapping, revascularization, and surgical ablation of reentry areas are reserved as elective procedures and are indicated only if drug therapy has failed. The surgical mortality rate is 10% to 20% and the freedom from recurrent arrhythmias and sudden death has been reported to be 75%. 153 
Two-Dimensional Echocardiography at Rest
Guidelines for the general use of echocardiography will be the subject of a future ACC/AHA Subcommittee publication. In the setting of acute myocardial infarction, two-dimensional echocardiography at rest has proved useful in the assessment of left ventricular function and risk stratification. Estimates of left ventricular systolic and diastolic volume and ejection fraction can be obtained by several techniques. Left ventricular function is more commonly and more usefully represented as a semiquantitative "wall motion index," wherein a numeric value representing hypokinesia, akinesia, or dyskinesia is visually assigned to wall segments.190 Predischarge two-dimensional echocardiography at rest can identify patients at higher risk of death, recurrent infarction, or development of congestive heart failure in the following 17 to 21 months.202'2w More importantly, a normal wall motion index early in infarction identifies a low risk subgroup that remained free of complications with a negative predictive accuracy of 95%. 208 Unlike radionuclide ventriculography, two-dimensional echocardiography detects wall thinning as well as abnormal wall motion. Disproportionate infarction expansion and ventricular dilation can be detected and are associated with a significant 2-month mortality rate.209 Furthermore, the detection of asynergy remote from the area of infarction on an echocardiogram identifies patients with multivessel disease and residual myocardium in jeopardy from ischemia.210 Twodimensional echocardiography can readily detect the following complications of infarction: rupture of the ventricular septum, papillary muscle or left ventricular free wall, left ventricular aneurysm or pseudoaneurysm, mural thrombus formation, infarct extension or expansion, and right ventricular infarction.21 ' The advantages of two-dimensional echocardiography include its portability and ease of performance. It can be used in the coronary care unit on very sick patients and can be repeated as necessary. It is painless and relatively inexpensive. Limitations include technical difficulties in obtaining interpretable studies in some patients with unusual body habitus or overlying lung tissue obscuring the echocardiographic window. 21 Ambulatory Continuous Electrocardiographic Monitoring Guidelines for ambulatory electrocardiography have been previously published.212 Twenty-four-hour Holter monitoring before discharge detects less than one premature ventricular complex per hour in >50% of patients after infarction. These low risk patients have a 2-year mortality rate of about 5%.6O The 15% to 25% of postinfarction patients found to have .10 premature ventricular complexes per hour on Holter monitoring have a 2-year mortality rate >20%.174,177 Even as few as one to three premature ventricular complexes per hour and certainly more than three premature ventricular complexes or a single ventricular premature couplet in a 24-hour recording markedly increases the risk of death over a follow-up period of several years. 213, 214 Increasing complexity of the ventricular arrhythmia (pairs and runs of ventricular tachycardia) is associated with decreasing survival. 180, 190, 215 Although ventricular ectopic activity is strongly associated with left ventricular dysfunction, multiple regression analysis in several large studiesl75,180,212-215 has shown it to be an independent risk factor for death after acute myocardial infarction. Furthermore, although the risk of death is greatest in patients with both complex ectopic activity and left ventricular dysfunction, the risk ratio was higher in patients with complex ectopic beats, even if they were at low risk by all other criteria. In these clinically uncomplicated patients, ectopic activity was infrequent, but when present it quadrupled the risk of death. 215 Electrophysiologic testing. This has also been utilized to stratify patients with ventricular ectopic activity and coronary artery disease. When programmed ventricular stimulation induced sustained ventricular tachyarrhythmia, the 1-year mortality rate, even on antiarrhythmic therapy, exceeded 30% versus 2% for patients with noninducible arrhythmias. 216 Because there are no randomized trials available to support the validity of this approach, however, the application of electrophysiologic study to evaluate ventricular ectopic activity occurring late after acute myocardial infarction remains controversial. 48 There is no indication for the use of electrophysiologic study to evaluate ventricular tachycardia or cardiac arrest in the acute phase of myocardial infarction (c48 hours).48 Signal-averaged electrocardiography is another promising technique that may prove beneficial in defining a subset of patients at high risk for sustained ventricular tachycardia.217
Whether antiarrhythmic therapy with encainide, flecainide, or moricizine can be expected to improve the survival of patients with significant ventricular arrhythmias is the subject of a randomized multicenter study, the Cardiac Arrhythmia Suppression Trial (CAST/NHLBI). 218 Preliminary results from that trial reveal an increased incidence of sudden death in patients treated with encainide or flecainide as compared with placebo-treated control subjects. All patients had demonstrated suppression of the ventricular arrhythmias before randomization to drug or placebo. Only 20% of the patients had nonsustained ventricular tachycardia and most had isolated premature ventricular beats. This study shows that these class IC antiarrhythmic agents should not be used in postmyocardial infarction patients with asymptomatic ventricular arrhythmias. 218 The study does not provide any evidence that suppression of such arrhythmias has a positive therapeutic effect despite the evidence that these arrhythmias define a group of patients at increased risk of sudden death. There is no evidence that any drug, with the possible exception of fl-blockers, alters the incidence of sudden death.
The Holter recording contains other information of value beyond documenting the frequency of premature ventricular complexes. The Holter monitor can be programmed to compute heart rate variability (standard deviation of all RR intervals in sinus rhythm). In a large trial,219 heart rate variability had the strongest univariate correlation with mortality of all the variables analyzed (greater than any grade of premature ventricular complexes, rales, and left ventricular ejection fraction <30%). This probably represents decreased vagal tone and increased sympathetic activity during ischemia, which would tend to promote ventricular fibrillation. ST segment shifts detected on calibrated continuous ambulatory ECG recording after infarction seem to represent ischemia that is frequently silent. Such changes are associated with a significantly increased 1-year mortality rate.220
Recommendations for 24-Hour Ambulatory Continuous Electrocardiography Class IIa 1. After myocardial infarction, patients with moderate to severe left ventricular dysfunction for prognostic assessment. 2. After myocardial infarction, patients with significant ventricular ectopic activity in the coronary care unit or stepdown telemetry unit for prognostic assessment. Class IIb 1. After myocardial infarction, patients to determine heart rate variability for prognostic assessment. 2. High risk postmyocardial infarction patients as a screen for silent ischemia. Class III 1. Uncomplicated ambulatory patients after discharge as a routine screen.
Summary
As noted at the beginning of this section, many of the described techniques are duplicative and the clinician must choose the tests that are cost-effective, are most accurate in his or her environment, and will lead to clinical decisions that can modify outcome or at least make a major impact on prognostication. One needs to decide if cardiac catheterization is indicated during the initial hospitalization or early convalescence and this frequently can be done by clinical assessment and data collected early in the initial hospitalization. Patients with an uncomplicated course and not considered for early catheterization need evaluation of left ventricular function either by echocardiography or radionuclide ventriculography and a search for evidence of myocardium at risk for new infarction by use of one of the three exercise strategies proposed.
If there is electrical instability manifested by complex ectopic beats or frequent ventricular premature beats during the later course of the infarction, a 24-hour ambulatory ECG recording is indicated. If there are runs of ventricular tachycardia, further electrophysiologic studies may be indicated, but it must be realized that there are no large trials to support the efficacy of antiarrhythmic therapy in the asymptomatic group of such patients after myocardial infarction. Studies showing efficacy of suppression of inducible sustained ventricular tachycardia have all been done in patients with chronic ischemic heart disease.
There are those who recommend routine convalescent cardiac catheterization and coronary angiography. This would eliminate the need for much of the noninvasive testing and eliminate exercise testing strategies in those selected immediately for surgical or angioplasty intervention. Cost-effectiveness is used as an argument, but we are not ready to recommend such a routine course because outcome data are not available as yet to support this aggressive strategy.
Coronary Angiography
Guidelines for the utilization of coronary angiography have been previously published. 221 In essence, all of the risk stratification efforts described using clinical assessment, exercise testing, radionuclide imaging, echocardiography, and Holter monitoring have been directed at defining a subset of patients after infarction at high risk for complications or premature death who would be candidates for coronary angiography to determine the potential for revascularization. The prognosis in the first year after infarction is directly related to the extent of coronary obstruction and the degree of left ventricular dysfunction documented at angiography.176,222 The costeffectiveness of various management alternatives after uncomplicated myocardial infarction has been analyzed using a theoretic model. 223 The most costeffective strategy was that which screened patients with treadmill exercise testing (with thallium added where indicated) and recommended coronary angiography and revascularization in all but those patients who had unequivocally negative studies. factors in this report. We believe strongly that this is a major task for the clinician discharging and following up the patient after monitoring his or her infarction, but because of space limitations we have left this task to other reports. We urge clinicians to become involved in treatment of lipid abnormalities, stopping smoking, treating hypertension, weight control, exercise, prescriptions, and seeing that this modification is a lifestyle change rather than just a temporary change induced by the fright of the acute episode. 
